Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice

Journal of Gene Medicine

Volumn 11, Issue 11, 2009, Pages 1020-1029

  Ishiwata, Akira ^a   Mimuro, Jun ^a   Mizukami, Hiroaki ^a   Kashiwakura, Yuji ^a   Takano, Katsuhiro ^a   Ohmori, Tsukasa ^a   Madoiwa, Seiji ^a   Ozawa, Keiya ^a   Sakata, Yoichi ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Adeno associated virus vector; Factor VIII; Gene therapy; Hemophilia A

Indexed keywords

ALPHA 1 ANTITRYPSIN; BETA ACTIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENHANCER REGION; GENE EXPRESSION; HEMOPHILIA A; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TISSUE SPECIFICITY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ACTINS; ALPHA 1-ANTITRYPSIN; ANIMALS; DEPENDOVIRUS; DOGS; FACTOR VIII; GENETIC VECTORS; HUMANS; LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROMOTER REGIONS, GENETIC;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 72949114341     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1391     Document Type: Article

References (40)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-1779.
2. Pasi KJ. Gene therapy for haemophilia. Br J Haematol 2001; 115: 744-757.
3. VandenDriessche T, Collen D, Chuah MK. Gene therapy for the hemophilias. J Thromb Haemost 2003; 1: 1550-1558.
4. Chuah MK, Collen D, Vandendriessche T. Preclinical and clinical gene therapy for haemophilia. Haemophilia 2004; 10(Suppl4): 119-125.
5. Chuah MK, Collen D, VandenDriessche T. Clinical gene transfer studies for hemophilia A. Semin Thromb Hemost 2004; 30: 249-256.
6. Hasbrouck NC, High KA. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects. Gene Ther 2008; 15: 870-875.
7. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
8. Jiang H, Pierce GF, Ozelo MC, et al. Evidence ofmulti year factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006; 14: 452-455.
9. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
10. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12: 342-347.
11. Lu Y. Recombinant adeno-associated virus as delivery vector for gene therapy - a review. Stem Cells Dev 2004; 13: 133-145.
12. Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med 2003; 9: 1015-1019.
13. Nakai H, Yant SR, Storm TA, et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75: 6969-6976.
14. Kumaran V, Benten D, Follenzi A, et al. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost 2005; 3: 2022-2031.
15. Sarkar R, Mucci M, Addya S, et al. Long-term efficacy of adenoassociated virus serotypes 8 and 9 in hemophilia a dogs and mice. Hum Gene Ther 2006; 17: 427-439.
16. Gnatenko DV, Wu Y, Jesty J, et al. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus. Thromb Haemost 2004; 92: 317-327.
17. Ohmori T, Mimuro J, Takano K, et al. Efficient expression of a transgene in platelets using simian immunodeficiency virusbased vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J 2006; 20: 1522-1524.
18. Vandendriessche T, Thorrez L, Acosta-Sanchez A, et al. Efficacy and safety of adeno-associated viral vectors based on serotype 8 and 9 vs. lentiviral vectors for hemophilia B gene therapy. J Thromb Haemost 2007; 5: 16-24.
19. Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 2004; 103: 1253-1260.
20. Ishiwata A, Mimuro J, Kashiwakura Y, et al. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. Thromb Res 2006; 118: 627-635.
21. Simonet WS, Bucay N, Lauer SJ, et al. A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem 1993; 268: 8221-8229.
22. Dang Q, Walker D, Taylor S, et al. Structure of the hepatic control region of the human apolipoprotein E/C-I gene locus. J Biol Chem 1995; 270: 22577-22585.
23. Allan CM, Taylor S, Taylor JM. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J Biol Chem 1997; 272: 29113-29119.
24. Mimuro J, Muramatsu S, Hakamada Y, et al. Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter. Gene Ther 2001; 8: 1690-1697.
25. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-121.
26. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670-2676.
27. MiaoCH, Ohashi K, PatijnGA, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther 2000; 1: 522-532.
28. Cao O, Dobrzynski E, Wang L, et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 2007; 110: 1132-1140.
29. Dobrzynski E, Mingozzi F, Liu YL, et al. Induction of antigenspecific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood 2004; 104: 969-977.
30. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-1356.
31. Brown BD, Sitia G, Annoni A, et al. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood 2007; 109: 2797-2805.
32. Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-2757.
33. Madoiwa S, Yamauchi T, Hakamata Y, et al. Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A. J Thromb Haemost 2004; 2: 754-762.
34. Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood 2005; 105: 4865-4870.
35. Flotte TR, Afione SA, Solow R, et al. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J Biol Chem 1993; 268: 3781-3790.
36. Haberman RP, McCown TJ, Samulski RJ. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J Virol 2000; 74: 8732-8739.
37. Miao HZ, Sirachainan N, Palmer L, et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412-3419.
38. Dooriss KL, Denning G, Gangadharan B, et al. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A. Hum Gene Ther 2009; 20: 465-478.
39. Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005; 79: 214-224.
40. Cao B, Bruder J, Kovesdi I, et al. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy. Gene Ther 2004; 11: 1321-1330.